Tumia R et al. also reported that high eIF3a expression increases radiotherapy and chemotherapy responses in patients with breast, gastric, lung, and ovarian cancer (Tumia et al., 2020), further suggesting that eIF3a may affect patient responses to treatments. This evidence concerns the gene EIF3A and ovarian cancer.